Cargando…

CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析

OBJECTIVE: To analyze the clinical features and prognosis of acute lymphoblastic leukemia patients with immunophenotype of CD10(−)pre-B (CD10(−) pre B-ALL). METHODS: 6 adult cases with CD10(−) pre B-ALL immunophenotypes were analyzed retrospectively, related literatures were reviewed to clarify thes...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348396/
https://www.ncbi.nlm.nih.gov/pubmed/28219219
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.01.004
_version_ 1783556815710060544
collection PubMed
description OBJECTIVE: To analyze the clinical features and prognosis of acute lymphoblastic leukemia patients with immunophenotype of CD10(−)pre-B (CD10(−) pre B-ALL). METHODS: 6 adult cases with CD10(−) pre B-ALL immunophenotypes were analyzed retrospectively, related literatures were reviewed to clarify these kind of patients' clinical features and prognosis. RESULTS: CD10(−) pre B-ALL occurred in 1.5% of ALL, 1.8% of B-ALL and 11.5% of pre B-ALL respectively. All the 6 patients were male with the median age as 33.5 years old, the median white blood cells was 101.78×10(9)/L, MLL-AF4 fusion transcripts were evident in all cases. Complete remission (CR) was achieved in 5 patients after first induction chemotherapy, 1 patient failed to respond to induction therapy, and got CR after 3 courses of chemotherapy. 2 patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR(1), 1 patient relapsed in the short term and underwent allo-HSCT in CR(2). 1 patient was still waiting for allo-HSCT. Of the 2 patients who didn't receive transplantation, 1 died following a relapse, the other remained to be in CR. CONCLUSION: CD10(−) pre B-ALL was a rare but distinct subtype in adult ALL characterized by male dominance, high onset white blood cells and MLL rearrangement rate. Conventional chemotherapy produced a high response rate but more likely relapse, allo-HSCT may have the potential to improve the prognosis of these patients.
format Online
Article
Text
id pubmed-7348396
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73483962020-07-16 CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the clinical features and prognosis of acute lymphoblastic leukemia patients with immunophenotype of CD10(−)pre-B (CD10(−) pre B-ALL). METHODS: 6 adult cases with CD10(−) pre B-ALL immunophenotypes were analyzed retrospectively, related literatures were reviewed to clarify these kind of patients' clinical features and prognosis. RESULTS: CD10(−) pre B-ALL occurred in 1.5% of ALL, 1.8% of B-ALL and 11.5% of pre B-ALL respectively. All the 6 patients were male with the median age as 33.5 years old, the median white blood cells was 101.78×10(9)/L, MLL-AF4 fusion transcripts were evident in all cases. Complete remission (CR) was achieved in 5 patients after first induction chemotherapy, 1 patient failed to respond to induction therapy, and got CR after 3 courses of chemotherapy. 2 patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR(1), 1 patient relapsed in the short term and underwent allo-HSCT in CR(2). 1 patient was still waiting for allo-HSCT. Of the 2 patients who didn't receive transplantation, 1 died following a relapse, the other remained to be in CR. CONCLUSION: CD10(−) pre B-ALL was a rare but distinct subtype in adult ALL characterized by male dominance, high onset white blood cells and MLL rearrangement rate. Conventional chemotherapy produced a high response rate but more likely relapse, allo-HSCT may have the potential to improve the prognosis of these patients. Editorial office of Chinese Journal of Hematology 2017-01 /pmc/articles/PMC7348396/ /pubmed/28219219 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.01.004 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title_full CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title_fullStr CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title_full_unstemmed CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title_short CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
title_sort cd10阴性的前b急性淋巴细胞白血病的临床特征以及预后分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348396/
https://www.ncbi.nlm.nih.gov/pubmed/28219219
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.01.004
work_keys_str_mv AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī
AT cd10yīnxìngdeqiánbjíxìnglínbāxìbāobáixuèbìngdelínchuángtèzhēngyǐjíyùhòufēnxī